IMFAR Special Interest Group, 2017
San Francisco, CA
May 13, 2017
Summary: 71 people attended and signed in to the SIG, not counting presenters and organizers. Just under half were considered early career scientists. Almost everyone indicated that they wanted to continue to participate in ongoing discussions and planning of activities that developed as a result of the SIG.
Presentation of mission and accomplishments of some of the Patient Advocacy Groups
Shafali Jeste, UCLA
Steve Roberds, TS Alliance
John Spiro, Simons Foundation
Geraldine Bliss, PMS Foundation
Vanessa Vogel-Farley, Dup15q Alliance
Facilitate a more direct dialogue between PAGs and researchers and clinicians who study and care for these populations
Discuss and develop strategies around central themes and issues faced by every group
Shafali Jeste, PhD, of UCLA speaking.
Breakout groups for discussion on topics of interest
Registries, led by Megan O’Boyle, Stelios Georgiades and Audrey Thurm:
Create a list of PAG registries (and their contents) in order to make the research community aware of the resources and facilitate cross-disease analysis
Propose the “next generation” of PAG registries, possibly using a tiered model in which all PAG’s collect consistent basic information, along with disorder-specific additional information
Create an over-arching shared database that all PAG’s can enter their information into in order to facilitate cross-disease analysis and reduce burden on families
Biorepositories, led by Mat Pletcher and Jennifer Lowe:
Inconsistent sharing of biological resources (animal models, tissues, data)
No centralized information regarding availability and location of biological resources
Limited cross-syndrome studies
Create a list of biorepositories (and their contents) in order to make the research community aware of the resources and facilitate cross-disease analysis
Mandate and enforce data sharing for animal models, tissues and other biological data
Propose an RFA for cross-syndrome studies
Mandate data sharing and timeline on repository materials in grants, and/or partner on a centralized repository
Clinical Trials, led by Deborah Pearson and Donna Murray:
Lack of coordination among researchers, clinicians, PAGs and patients/families
Lack of consistent pipeline for dissemination of research and communication of findings with families and community
Lack of meaningful clinical endpoints/outcome measures, particularly in syndromes where standardized assessments provide limited information
Engage a larger group of advocates (self and parents) to provide input
Create a centralized resource for dissemination of research findings (similar to the clinical trials network previously created by Autism Speaks). This should include research summaries on a variety of topics (written for families and clinicians) along with information on how to be a good consumer of research.
Create guidelines for best practices regarding assessments and clinical endpoints/outcome measures
Establish a common registry for natural history and clinical trials data across organizations, as this will help identify outcome measures
Alycia Halladay, PhD, of the Autism Science Foundation speaking.
Feedback from participants:
The participants indicated that they thought this SIG could be most productive by increasing opportunities for collaboration including, but not limited to: multidisciplinary approaches, data sharing, and combination of data sets. Another common theme was the need for PAGs to help build or support infrastructure such as common core data collection protocols, a registry template, open access tools, and outcome measures. They also stressed the importance of providing information to the community for understanding of the importance of research in this area, as well as more basic educational tools. Finally, they suggested that leadership of the SIG write a white paper to address one or more of the challenges and proposed solutions in the key areas discussed in the breakout groups.
The individuals who participated also indicated that they would like more time for discussion in the future. Since that is not really feasible at a SIG, the group is going to consider opportunities for ongoing engagement such as webinars, teleconferences, or opportunities to meet at other meetings like ASHG or SFN before the next IMFAR in the Netherlands.